YS
Income statement / Annual
Last year (2023), YS Biopharma Co., Ltd.'s total revenue was $687.20 M,
an increase of 36.63% from the previous year.
In 2023, YS Biopharma Co., Ltd.'s net income was -$145.48 M.
See YS Biopharma Co., Ltd.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
| Period Ended |
03/31/2023 |
03/31/2022 |
03/31/2021 |
| Operating Revenue |
$687.20 M
|
$502.95 M
|
$257.02 M
|
| Cost of Revenue |
$153.36 M |
$117.07 M |
$59.66 M |
| Gross Profit |
$533.84 M |
$385.88 M |
$197.36 M |
| Gross Profit Ratio |
0.78 |
0.77 |
0.77 |
| Research and Development
Expenses |
$318.70 M
|
$211.22 M
|
$94.39 M
|
| General & Administrative
Expenses |
$81.76 M
|
$107.05 M
|
$138.89 M
|
| Selling & Marketing
Expenses |
$251.56 M
|
$165.72 M
|
$69.44 M
|
| Selling, General &
Administrative Expenses |
$333.32 M
|
$272.77 M
|
$208.33 M
|
| Other Expenses |
-$199,452.00 |
-$2.41 M |
-$22.36 M |
| Operating Expenses |
$647.15 M |
$481.82 M |
$319.68 M |
| Cost And Expenses |
$800.51 M |
$598.89 M |
$379.33 M |
| Interest Income |
$0.00 |
$0.00 |
$0.00 |
| Interest Expense |
$30.86 M |
$2.72 M |
$29.69 M |
| Depreciation &
Amortization |
$36.69 M
|
$31.15 M
|
$27.91 M
|
| EBITDA |
-$76.82 M
|
-$67.20 M
|
-$116.78 M
|
| EBITDA Ratio |
-0.11 |
-0.13 |
-0.45 |
| Operating Income Ratio
|
-0.2
|
-0.24
|
-0.49
|
| Total Other
Income/Expenses Net |
-$4.96 M
|
$17.89 M
|
-$48.52 M
|
| Income Before Tax |
-$144.35 M |
-$101.07 M |
-$174.37 M |
| Income Before Tax Ratio
|
-0.21
|
-0.2
|
-0.68
|
| Income Tax Expense |
$1.13 M |
$4.94 M |
$17.45 M |
| Net Income |
-$145.48 M |
-$106.00 M |
-$191.83 M |
| Net Income Ratio |
-0.21 |
-0.21 |
-0.75 |
| EPS |
-1.56 |
-1.15 |
-2.08 |
| EPS Diluted |
-1.56 |
-1.15 |
-2.08 |
| Weighted Average Shares
Out |
$93.06 M
|
$92.17 M
|
$92.17 M
|
| Weighted Average Shares
Out Diluted |
$93.06 M
|
$92.17 M
|
$92.17 M
|
| Link |
|
|
|
